Patients with advanced abdominal cancers who are not candidates for tumor-removing surgery now have access to a treatment that may help control disease within the abdomen, reduce symptoms, preserve quality of life, and potentially extend survival.
Commentary|Videos|February 19, 2026
Patient Selection Considerations for the Bionic Breast Project
Author(s)Stacy Tessler Lindau, MD, MA
Fact checked by: Kyle Doherty
Stacy Tessler Lindau, MD, MA, discusses which patients would be strong fits for the Bionic Breast project.
Advertisement
Stacy Tessler Lindau, MD, MA, discusses which patients should consider enrolling in the Bionic Breast project. She notes that the project is currently focusing on patients who are willing to connect with study investigators twice weekly for several weeks to do electrical testing of the neuroprosthetic implant. Patients will also participate in phone interviews and keep a journal documenting their experience with the procedure.
Advertisement
Related to this article
The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.
Dabogratinib led to a high rate of responses FGFR3-altered low-grade intermediate-risk non–muscle-invasive bladder cancer.
Mipletamig plus venetoclax and azacitidine produced a CBR of 93% in induction-ineligible, TP53-mutated acute myeloid leukemia.
A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.
Signatera assay ctDNA testing showed stronger prognostic and predictive value than PET/CT imaging across lymphomas.
D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
3
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
4
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
5